During Tuesday’s trading session, the shares of a pharmaceutical company engaged in the development and manufacture of quality finished dosages moved up by around 10 percent on BSE, after securing an Indian Patent for a Novel Topical Solution for Diabetic Neuropathic Pain.
Price Movement:
With a market capitalisation of Rs. 382.2 crores, at 12:21 p.m., the shares of Lyka Labs Limited were trading in the green at Rs. 107.1, up by nearly 6 percent, as compared to its previous closing price of Rs. 101.05. The stock has delivered negative returns of nearly 32 percent YTD, but gained around 1.4 percent in a month.
What’s the News:
In its latest exchange disclosure, Lyka Labs Limited announced securing a grant of an Indian Patent for its proprietary product, Pregabalin Gel 8%, with patent protection valid through 2043.
Lyka Labs has conducted clinical studies supporting the efficacy, safety, and patient convenience of Pregabalin Gel 8%, positioning it as a promising alternative for individuals suffering from chronic diabetic neuropathic conditions.
About the Product:
Pregabalin Gel 8% is a topical formulation specifically developed to address diabetic neuropathic pain. The formulation received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) in October 2024, authorizing its manufacture and sale in India.
The product was officially launched in December 2024 by Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare under a P2P (Product-to-Product) license from Lyka Labs.
This gel formulation represents a first-of-its-kind innovation in India, offering targeted pain relief by delivering pregabalin directly to the affected area. This localized approach is designed to reduce systemic exposure and related side effects commonly associated with oral formulations.
Financial Performance:
Lyka Labs reported a marginal growth in revenue from operations, experiencing a year-on-year rise of nearly 3.7 percent, from Rs. 32.6 crores in Q3 FY24 to Rs. 33.8 crores in Q3 FY25.
Similarly, the company’s net profit increased during the same period from Rs. 1.8 crores to Rs. 2.7 crores, representing a growth of nearly 50 percent YoY.
About the Company:
Lyka Labs Limited is a pharmaceutical company engaged in the business of developing, manufacturing and marketing of quality finished dosages, with a well-diversified business model in terms of markets, therapies and products.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
